Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced Malignancies|Metastatic Cancer
Interventions: DRUG: INCAGN01876|DRUG: Nivolumab|DRUG: Ipilimumab
Sponsor: Incyte Biosciences International Sàrl